Search clinical trials for: MK0677

Total 140 results

Merck Sharp & Dohme LLC

Terminated

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Hip Fracture

Germany, Norway, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

MK0767 in Type 2 Diabetes (0767-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Study A - MK0767 Monotherapy Study

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders
Merck Sharp & Dohme LLC

Terminated

MK0767 and Sulfonylurea Combination Study (0767-027)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

Dyslipidemia in Type 2 Diabetes (0767-034)

Dyslipidemia | Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

Migraine
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Anxiety Disorder (0777-022)

Generalized Anxiety Disorder
Merck Sharp & Dohme LLC

Terminated

Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 and Metformin Combination Study (0767-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Terminated

MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)

Migraine
Merck Sharp & Dohme LLC

Completed

Bioequivalence of Two Tablet Forms of MK0974 (0974-045)

Migraine
Merck Sharp & Dohme LLC

Completed

The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)

Atherosclerosis
Merck Sharp & Dohme LLC

Terminated

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Neuralgia, Postherpetic
Merck Sharp & Dohme LLC

Completed

MK0457 in Patients With Leukemia (0457-003)

Myelodysplastic Syndromes | Myelogenous Leukemia, Chronic | Chronic Myelogenous Leukemia in Blast Crisis | Lymphocytic Leukemia, B Cell, Acute
Merck Sharp & Dohme LLC

Terminated

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

Leukemia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)

Osteoarthritis
Merck Sharp & Dohme LLC

Completed

MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)

Asthma
Merck Sharp & Dohme LLC

Completed

A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Completed

MK0686 in Postsurgery Dental Pain (0686-002)

Pain, Postoperative
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

Asthma
Merck Sharp & Dohme LLC

Completed

Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)

Asthma
Merck Sharp & Dohme LLC

Terminated

The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

Asthma
Merck Sharp & Dohme LLC

Completed

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

Schizophrenia | Paranoid Schizophrenia
Merck Sharp & Dohme LLC

Terminated

MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

Colorectal Cancer | Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

Anxiety Disorder
Merck Sharp & Dohme LLC

Terminated

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Neoplasms
Merck Sharp & Dohme LLC

Terminated

Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC
Bristol-Myers Squibb

Terminated

An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

Metabolic X Syndrome Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Obesity
Organon and Co

Completed

A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Organon and Co

Completed

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Paget's Disease of Bone
Merck Sharp & Dohme LLC

Completed

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Schizophrenia
University of Virginia
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Completed

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

End Stage Renal Disease | Chronic Kidney Disease

United States
Hillel Yaffe Medical Center

Unknown

Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

Ovarian Cancer

Israel
University of Virginia
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Withdrawn

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Chronic Kidney Disease | Kidney Disease

United States
Bennett, Robert, M.D.
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Fibromyalgia

United States
Organon and Co

Completed

Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)

Lipid Metabolism Disorder
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Cancer, Advanced
Organon and Co

Completed

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

Acute Pain Following a Total Abdominal Hysterectomy
Organon and Co

Completed

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Hypercholesterolemia

3

Subscribe